Advanced biological long-term anti AIDS drug ibovetai holds the mid-term coordination meeting of phase III clinical trials

After 12 years of hard research and development, the world's first long-term anti AIDS drug, ibovetai, is expected to complete clinical research and enter the market in 2016 Ibovetai is a long-acting HIV (human immunodeficiency virus) fusion inhibitor Its expected clinical indications are to treat AIDS and prevent HIV infection On November 16, 2013, the drug began the clinical phase 3 trial, which is the first anti AI new drug entering the clinical phase 3 in China AI Bo Wei Tai was developed by Nanjing frontier Biotechnology Co., Ltd located in Jiangning District Xie Dong, chairman and chief scientist of the company, said that from the results of phase 2 clinical trials, AI Bo Wei Tai has three distinct characteristics: first, it has a new mechanism of action, which has been proved by experiments that AI Bo Wei Tai's novel mechanism of action makes it effective for all known drug-resistant HIV strains The second feature is long-term Compared with other anti AI drugs 1 - 3 times a day, the frequency of Abbott Did Tai is once a week Because of its long-term characteristics, ibovetai can also be used to prevent high-risk groups from contracting HIV Another characteristic of ibovetai is its unique target The reporter learned that ibovetai can inhibit the replication and transmission of HIV in the human body by controlling the gp41 protein of HIV and preventing them from binding with human T cells The results of the two phase clinical trials that have been completed before this time show that the efficacy of the combination of ibovetai and another drug for the treatment of human immunodeficiency virus, klitschke, is unexpected: after 7 weeks of treatment, not only the HIV virus in all patients has been reduced by 99%, but also the viral load in 56% of patients has been reduced below the detection line, that is to say, the standard method can not detect it At present, there are 35.3 million people infected with HIV, 2.3 million new infections and 1.6 million people died of AIDS At present, there are 26 kinds of synthetic drugs for AIDS treatment in the world, all of which are developed by foreign enterprises Aibo Weitai has global independent intellectual property rights Xie Dong disclosed yesterday that at present, the 3-phase clinical treatment of ibovetai is under intense development in 12 clinical centers in China If all goes well, new drugs will be declared next year, which means that patients will be able to use "made in China" long-term anti AIDS drugs from next year Industry insiders predict that once the successful industrialization of Aibo Weitai, it will achieve "zero breakthrough" of China's new anti AI drugs, and the cumulative sales volume is expected to reach 20 billion yuan "Ibovetai can not only meet the urgent needs of first-line treatment failure patients for new drugs, but also hope to break the monopoly of foreign patent drugs." One industry expert said.